One Minute Heart Rate Variability Quantification in Airway Obstruction Model (RRV Airway)
Primary Purpose
Airway Obstruction
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Heart rate variability analysis
Sponsored by
About this trial
This is an interventional basic science trial for Airway Obstruction
Eligibility Criteria
Inclusion Criteria:
- 18 30 years old
- healthy
Exclusion Criteria:
- heart disease
- lung disease
- BMI > 26
- ECG abnormalities
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Healthy volunteers
Arm Description
Healthy volunteers
Outcomes
Primary Outcome Measures
Low Frequency Power Spectral Density
FFT HRV Low Frequency Power Spectral Density
Secondary Outcome Measures
Full Information
NCT ID
NCT03733704
First Posted
November 4, 2018
Last Updated
November 6, 2018
Sponsor
Rambam Health Care Campus
1. Study Identification
Unique Protocol Identification Number
NCT03733704
Brief Title
One Minute Heart Rate Variability Quantification in Airway Obstruction Model
Acronym
RRV Airway
Official Title
One Minute Heart Rate Variability Quantification in Airway Obstruction Model
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
May 20, 2015 (Actual)
Primary Completion Date
June 11, 2015 (Actual)
Study Completion Date
July 1, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rambam Health Care Campus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
40 healthy volunteers underwent a trial of obstructed breathing through an eighteen cm long, four mm internal diameter tube. Heart rate was recorded during three consecutive sets comprised of one minute control followed by one minute of obstructed breathing, with one minute of rest between sets. Time and frequency domain analysis were used to compare HRV during control versus obstructed breathing.
Detailed Description
Following approval by the Institutional Review Board, the study was performed in a prospective cross-over, longitudinal cohort manner. Healthy volunteers aged between 20 and 40 years were included. Each participant signed an informed consent. Exclusion criteria were respiratory or cardiac pathology, diabetes, a body mass index lower than 18 or higher than 26 kg/m2, chronic medical conditions with significant involvement of the sympathetic or parasympathetic systems (e.g. diabetes), obstructive sleep apnea, use of medications with either cardiovascular or respiratory effects, and ECG abnormalities including heart rate other than sinus rhythm, atrioventricular conduction blocks, intrafascicular conduction delays or prolonged QT interval (the time between consecutive Q and T waves on the electrocardiogram).
Initially, each volunteer underwent an ultrasound evaluation (SonoSite™ M-Turbo™ ultrasound machine, SonoSite, Bothell, Washington, USA) of the lungs using a high frequency linear probe at mid clavicular lines to exclude pneumothorax, an apical view of the heart using a curve-linear probe to exclude pericardial effusion. A twelve lead ECG was obtained and analyzed to exclude rate or conduction abnormalities. Noninvasive blood pressure and oxygen saturation were recorded in all subjects throughout the study to identify and prevent any complication.
A three lead ECG and spirometry were obtained in supine position with the upper body raised by 30 degrees. Data was collected using a Datex AS/3 monitor (Datex Ohmeda Medical Equipment, GE Healthcare, USA). The data was recorded using a digital to analog acquisition card (NI-6008, National Instruments™, Austin, Texas, USA) and a Biosignal Logger of National Instruments™ Biomedical Workbench™ at a sampling rate of 500 Hertz (Hz). All experiments were performed at the same time of day (early afternoon), and under the same conditions (same place and experimental setup). Volunteers were instructed to refrain from smoking for 4 hours prior to participating in the study.
The airway obstruction was simulated by an 18 cm long, 4 mm internal diameter endotracheal tube, connected to a spirometry adaptor and an antimicrobial filter. During the obstructed breathing phase, the volunteers were directed to seal their lips tightly around the filter to prevent air leak and encouraged to reach a peak pressure of 30-40 cm H2O, using the instantaneous display on the spirometry monitor. Three sets were recorded for each volunteer; each set was comprised of one minute of normal unobstructed breathing that served as control, immediately followed by one minute of obstructed breathing. Following each set, the volunteers were allowed at least one minute of rest period to recover and return to their baseline breathing before the next set.
HRV analysis A detailed description of the means to measure and evaluate the significance of HRV can be found in the European Society of Cardiology and the North American Society of Pacing Electrophysiology Task Force on heart rate variability, standards of measurement and physiological interpretation and clinical use guidelines14. Briefly, the raw ECG signal was preprocessed (including high pass filtering to remove Baseline wandering and ECG feature identification) and the R-R intervals were extracted from the raw ECG signal using ECG Features Extractor of National Instruments™ Biomedical Workbench™ with threshold adjust factor of 0.1, a rough highest heart rate of 60 beats per minute, QRS frequency of 10-25 Hz and middle QRS onset and offset.
Evaluation of HRV is predominantly performed using time and frequency domains. It may be also performed using nonlinear methods; however, here the investigators concentrated on the more commonly used time and frequency domain methods. Time domain measures are based on the statistical analysis of the time interval between two adjacent QRS waves on the electrocardiogram complexes, referred to as R-R intervals (time between two consecutive R waves on the electrocardiogram). R-R intervals standard deviation (SD), root mean square of successive differences (RMSSD) between adjacent R-R intervals, number of pairs of successive R-R intervals that differ by more than 50 millisecond (NN50) and proportion of NN50 divided by total number of R-R intervals (pNN50) are routinely used to quantify HRV. Frequency domain employ mathematical manipulation to the signal, such as the fast Fourier transform (FFT), which converts the time function into a sum of sine waves of different frequencies. These are used to calculate the power spectral density in very low (VLF), low (LF) and high frequency (HF) ranges and provide a quantification of the physiological HRV-related effects. In this report the investigators did not include the VLF, as this value cannot be reliably measured with a brief measurement window of one minute. As HRV is clearly related to the heart rate, the investigators normalized the HF power and LF power to the heart rate15. The normalized values are referred to as HFnorm and LFnorm.
HRV parameters were calculated over one minute sampling window using the Heart Rate Variability Analyzer of National Instruments™ Biomedical Workbench™. Fast Fourier analysis was employed using a Hanning Window of 1024 samples with a 50% overlap, and with a 2 Hz interpolation rate and 1024 frequency bins. As suggested in the literature for the power spectral density calculation, HF was defined as 0.15-0.4 Hz, LF as 0.04-0.15 Hz and VLF as below 0.04 Hz14.
Respiratory rate calculation To evaluate the changes in respiration during the obstructed breathing the investigators calculated the respiratory rate during the control and obstructed breathing periods. the investigators used the raw ECG traces to calculate the respiratory rate16. This was done primarily based on the R wave amplitude, and calculating the number of local peaks in the sampling window. To obtain meaningful results the investigators chose the control and the obstructed breathing segments with the most obvious changes in the R wave amplitude. Using this methodology the investigators could reliably evaluate the respiratory rate in 33 subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Airway Obstruction
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Spontaneous ventilation via an obstructing plastic tube
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Healthy volunteers
Arm Type
Experimental
Arm Description
Healthy volunteers
Intervention Type
Diagnostic Test
Intervention Name(s)
Heart rate variability analysis
Intervention Description
Heart rate variability analysis extracted from ECG during normal and obstructed breathing
Primary Outcome Measure Information:
Title
Low Frequency Power Spectral Density
Description
FFT HRV Low Frequency Power Spectral Density
Time Frame
1 minute
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18 30 years old
healthy
Exclusion Criteria:
heart disease
lung disease
BMI > 26
ECG abnormalities
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30632302
Citation
Lehavi A, Golomb N, Leiba R, Katz YS, Raz A. One-minute heart rate variability - an adjunct for airway obstruction identification. Physiol Rep. 2019 Jan;7(1):e13948. doi: 10.14814/phy2.13948.
Results Reference
derived
Learn more about this trial
One Minute Heart Rate Variability Quantification in Airway Obstruction Model
We'll reach out to this number within 24 hrs